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Background. Antibiotic-tolerant bacterial persistence prevents treatment shortening in drug-susceptible tu-
berculosis, and accumulation of intracellular lipid bodies has been proposed to identify a persister phenotype
of Mycobacterium tuberculosis cells. In Malawi, we modeled bacillary elimination rates (BERs) from sputum
cultures and calculated the percentage of lipid body–positive acid-fast bacilli (%LB + AFB) on sputum smears.
We assessed whether these putative measurements of persistence predict unfavorable outcomes (treatment
failure/relapse).
Methods. Adults with pulmonary tuberculosis received standard 6-month therapy. Sputum samples were collected
during the first 8 weeks for serial sputum colony counting (SSCC) on agar and time-to positivity (TTP) measurement
in mycobacterial growth indicator tubes. BERs were extracted from nonlinear and linear mixed-effects models, respec-
tively, fitted to these datasets. The %LB + AFB counts were assessed by fluorescence microscopy. Patients were followed
until 1 year posttreatment. Individual BERs and %LB + AFB counts were related to final outcomes.
Results. One hundred and thirty-three patients (56% HIV coinfected) participated, and 15 unfavorable outcomes
were reported. These were inversely associated with faster sterilization phase bacillary elimination from the SSCCmodel
(odds ratio [OR], 0.39; 95% confidence interval [CI], .22–.70) and a faster BER from the TTP model (OR, 0.71; 95% CI,
.55–.94). Higher %LB +AFB counts on day 21–28 were recorded in patients who suffered unfavorable final outcomes
compared with those who achieved stable cure (P = .008).
Conclusions. Modeling BERs predicts final outcome, and high %LB + AFB counts 3–4 weeks into therapy may
identify a persister bacterial phenotype. These methods deserve further evaluation as surrogate endpoints for clinical
trials.
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Tuberculosis treatment takes at least 6 months. Shorter
treatment is required [1, 2], particularly in settings of
high tuberculosis/human immunodeficiency virus (HIV)
coinfection [3]. New compounds are under clinical eval-
uation [4, 5], but recent phase 3 trials of 4-month regi-
mens incorporating 8-methoxyfluoroquinolones resulted
in high relapse rates [6–8] despite promising phase 2
studies [9–12].New surrogate endpoints, measured early
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but predicting long-term efficacy, are needed to select better
drug combinations.
An obstacle to shorter therapy is bacillary persistence; antibiot-
ic-tolerant organisms without genotypic resistance may survive
drug pressure by entering a nonreplicating state [13,14].Regimens
to kill these bacteria are essential. Modeling bacillary elimination
rates (BERs) over 8 weeks may quantitate persistence more pre-
cisely than sputum culture conversion at a single time-point
and represent better surrogate endpoints [15, 16], particularly if
augmented by phenotypic labeling of persister bacteria.
One promising technique is serial sputum colony counting
(SSCC). Colony-forming units (CFUs) ofMycobacterium tuber-
culosis are counted after incubation on selective agar and bacil-
lary clearance is measured. Response to first-line therapy is
biphasic: a 5- to 7-day early bactericidal phase may represent
elimination of metabolically active organisms by isoniazid
[17], followed by a sterilization phase lasting many weeks,
which represents persister elimination by other drugs. This
nonlinear response, and high interindividual variability, neces-
sitates hierarchical mixed-effects modeling of sterilization phase
elimination rates (SPERs) to compare novel regimens [12, 18].
An alternative approach involves analyzing serial time-to-
positivity (TTP) results in the mycobacterial growth indicator
tube (MGIT) system [19, 20]. Liquid cultures remain positive
after solid media conversion, which may help study persistence.
However, neither SSCC nor MGIT-TTP data are validated to
predict relapse.
Identifying antibiotic-tolerant organisms requires single-cell
assessment. In vitro studies suggest that nonreplicating bacilli
survive physiological stress by upregulating triacylglycerol
(TAG) synthase genes, including tgs1, to accumulate cytoplasmic
TAG lipid bodies (LBs) [21–23]. Tgs1-expressing organisms
demonstrate tolerance to first-line antituberculosis drugs [21,
22], and isoniazid exposure may induce LB formation [24]. LBs
may phenotypically label persister cells, but only 1 study has de-
scribed LB-containing bacilli in clinical samples [23]. Serial anal-
ysis during tuberculosis treatment has never been undertaken.
We modeled SSCC and MGIT-TTP culture data from the
first 8 weeks of tuberculosis treatment in Malawian adults and
performed fluorescence microscopy to quantify LB-positive
acid-fast bacilli (%LB + AFB) on sputum smears. We consid-
ered whether these putative measurements of persistence pre-
dict clinical endpoints.
METHODS
Patient Recruitment and Follow-up
A prospective cohort study was conducted at Queen Elizabeth
Central Hospital in Blantyre, Malawi, from 2010 to 2012. Con-
senting adults aged 16–65 years with sputum smear–positive
pulmonary tuberculosis graded “++” or “+++” for AFB on
Ziehl–Neelsen microscopy were eligible [25]. Exclusion criteria
included hemoglobin level <6 g/dL, creatinine level >177 µmol/L,
total bilirubin level >51 µmol/L, alanine aminotransferase level
>200 IU/L, clinical status suggestive of imminent mortality
(World Health Organization Performance Score 4) [26], pregnan-
cy, tuberculosis treatment within 5 years, corticosteroid therapy, or
baseline resistance to rifampicin and isoniazid using the Genotype
MTBDRplus 2.0 line probe assay (LPA; Hain Life Sciences). Treat-
ment was according to National Tuberculosis Control Programme
guidelines. Fixed-dose combination tablets containing rifampicin,
isoniazid, pyrazinamide, and ethambutol were given for 8 weeks,
followed by fixed-dose combination tablets containing rifampicin
and isoniazid for 16 weeks [27]. All patients had point-of-care
HIV serology. Antiretroviral therapy (ART) was available accord-
ing to national protocols [28, 29].Chest radiographs were assessed
using a published method [30] to determine the percentage of
lung affected and the presence of ≥4-cm cavities.
Follow-up continued for 1 year after end of treatment (EOT).
Patients with negative tuberculosis sputum cultures from EOT
onward or who stopped coughing and remained well were de-
fined as having stable cure; those with positive culture at EOT
were deemed to have failed treatment; and those who were
culture negative at EOT but subsequently developed positive
cultures were considered to have relapsed.
Sputum Sample Collection and Processing
Patients were allocated sequentially to staggered, balanced sam-
pling blocks to maximize information for BER modeling [31].
Block 1 submitted sputum on days 0, 4, 14, 28, and 56 of ther-
apy. Block 2 was sampled on days 0, 2, 7, 21, and 49.
Twelve-hour overnight sputum collections were conducted as
previously described [18]. Two 1-mL aliquots were used for
SSCC plates and liquid cultures. The remainder was stored at
−20°C for LB microscopy. Initial sputum processing was
done within 24 hours.
All patients submitted spot sputum samples after 5 months of
therapy (EOT samples) to assess bacteriological cure. Those
with ongoing or recurrent symptoms submitted posttreatment
samples to test for relapse.
Sputum Bacteriology
The SSCC method was previously described [18]. One milliliter
of undecontaminated sputum was homogenized with an equal
volume of dithiothreitol (Oxoid). Five serial 10-fold dilutions
were prepared in phosphate-buffered saline (PBS). Fifty micro-
liters of neat sputum and each dilution was plated onto dupli-
cate plates of Middlebrook 7H11 oleic acid albumin agar media
made selective by addition of polymyxin B (200 U/mL), ticarcillin
(100 mg/L), trimethoprim (10 mg/L), and AmB (10–30 mg/L).
After 3 weeks’ incubation, dilutions yielding 10–100 colonies
were selected for counting. Average CFU/mL of sputum were
calculated from the 2 replicates.
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For liquid culture, 1 mL of specimen was decontaminated
with N-acetyl-L-cysteine/sodium hydroxide (NaOH) 3% and in-
oculated into MGITs (Becton Dickinson). TTP recorded by the
instrument was used as an inverse measure of bacterial growth.
Ziehl–Neelsen microscopy and MGIT TBc Identification Test
kits (Becton Dickinson) were used to confirm that positive iso-
lates represented pure growth of M. tuberculosis. Samples not
signaling positive at 7 weeks were regarded as “negative.”
Sputum samples from EOT and follow-up visits were decon-
taminated and inoculated on Lowenstein-Jensen media and in
MGIT.Mycobacterium tuberculosis growth from >1 culture rep-
resented failure or relapse, dependent on the timing of the first
positive specimen.
Fluorescence Auramine LipidTOX Red Sputum Microscopy
As fluorescence microscopy to quantitate bacillary subpopula-
tions is difficult on “scanty” slides, baseline assessment was re-
stricted to patients with smear “+++” pretreatment samples. For
serial analysis, all samples were reviewed from each patient with
an unfavorable outcomes whose sputum was graded “+++” at
baseline and at least “++” on 1 or more subsequent occasions.
These patients were randomly matched to 3 controls with the
same smear grading criteria, but who achieved stable cure.
We evaluated changes in the proportion of LB-positive cells,
rather than changes in the absolute numbers of AFB.
The Auramine LipidTOX Red method was adapted from an
“Auramine-Nile red” technique [32]. LipidTOX Red neutral
(LTR; Invitrogen) replaced Nile Red to stain intracellular lipid
because Nile Red is solvatochromatic, prone to photo bleaching,
and has emission spectrum overlap with auramine O [33, 34].
One milliliter of sputum aliquots was incubated with an equal
volume mixture of lipase (1 mg/kg) from Candida rugosa
(Sigma) and dithiothreitol for 1 hour to digest extracellular
lipid and liquefy the sample. Ten-microliter smears were heat-
fixed onto slides, flooded with auramine O for 10 minutes, de-
colorized with 0.5% acid alcohol for 2 minutes, reflooded with
LTR (1:200 dilution of stock solution in PBS) for 20 minutes,
and counterstained with 0.1% potassium permanganate for 45
seconds. Slides were washed in mycobacteria-free distilled water
after each step, protected from light, and read within 24 hours.
Smears were scanned systematically through a fluorescein
isothiocyanate filter using a Leica DMLB epifluorescence micro-
scope at ×1000 magnification. All fields containing auramine-
stained, yellow-green AFB were photographed using a Leica
DFC300FX R2 digital camera, then rephotographed through a
tetramethylrhodamine filter to capture LTR-stained red LBs.
Smears were examined for 15 minutes or until 100 sequential
AFB had been imaged. Organisms on paired images were LB
positive if ≥1 LB was seen inside the auramine-labelled bacillus
and LB negative if LBs were absent (example images are shown
in Supplementary Figure 1A–C). The %LB + AFB counts were
allocated to each slide as follows:
%LBþAFB¼ 100 Total LB positive AFB on all images
Total AFB on all images
 
:
Clinical details were blinded before staining. Duplicate smears
were made from each specimen and results expressed as mean
%LB + AFB counts. Microscopic images were assessed by 2 in-
dependent readers.
Data Analysis and Statistical Methods
The study endpoint was the composite “unfavorable” clinical out-
come of treatment failure or relapse. Nonparametric summary sta-
tistics were used to describe the data, multivariate logistic regression
to assess factors contributing to clinical outcome, and multivariate
linear regression to assess factors contributing to bacillary clearance
or %LB +AFB counts. Results were expressed as odds ratios (ORs)
or regression coefficients with 95% confidence intervals (CIs). Sig-
nificance was reported at P < .05. Interreader variability in %LB-
AFB counts was evaluated using Lin concordance coefficient (ρc)
and Bland and Altman 95% limits of agreement.
SSCC data modeling employed nonlinear mixed effects
(NLME) methods [16, 18, 23]. Patients with ≥2 positive counts
were included. Counts below the limit of detection (1.27 log10
CFU/mL) were accounted for using a partial likelihood method.
Multiexponential functions were fitted to pooled data by non-
linear least squares and compared using the Akaike information
criterion and residual plots. The function
log10CFU ¼ log10½ðeu1  eday  e
u2Þ þ ðeu3  eday  eu4Þ
was most appropriate and represented the anticipated biphasic
pattern of bacillary elimination. Parameters θ1–4, expressed on
the natural log scale, were transformed to AInt, α, BInt, and β
on the log10 scale for easier evaluation. Supplementary Figure 2A
interprets the model; the early bactericidal phase is represented
by the total baseline bacillary load (AInt) and early elimination
rate constant (α), whereas the sterilization phase is represented
by the baseline load of persister organisms (BInt) and late elim-
ination rate constant (β). Random effects on AInt, BInt, and β
described interpatient variability. Best linear unbiased estimates
of β were extracted for each individual to examine relationships
between the SPER and treatment outcome.
MGIT data modeling included patients with ≥2 TTP mea-
surements. A partial likelihood method was used to account
for TTP of negative results. Quadratic and spline functions
were used to test for curvature in the pooled dataset, but a linear
mixed-effects function of the form
TTP in days ¼ aþ bðweeks on therapyÞ
with random effects on a and b was appropriate. Supplementary
Figure 2B interprets the intercept (a) as a model-derived
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measurement of baseline TTP and the rate constant (b) as the
MGIT bacillary elimination rate (MBER). Unbiased MBER es-
timates were extracted for each patient to assess the relationship
between bacillary clearance and treatment outcome.
Analyses were performed in R version 2.15.2 [35]. The M3
method was required to fit the partial likelihood models in NON-
MEMVII version 2.0 with Pirana (Icon Development Solutions).
Ethical Approval
Ethical approval was given by the Liverpool School of Tropical
Medicine (protocol 09.67) and the College of Medicine Re-
search Ethics Committee, University of Malawi (P.01/10/855).
RESULTS
Patients and Samples
Figure 1 describes recruitment, follow-up, and outcomes. Of
287 patients screened, 169 were recruited and 36 withdrew be-
fore study completion. Of the remaining 133, there were 118
(89%) stable cures and 15 (11%) unfavorable outcomes (10 fail-
ures and 5 relapses, all within 6 months of EOT).
Further analysis was undertaken on patients reaching a study
endpoint. Median age was 31 years, and 89 (67%) were male.
Median body mass index at baseline was 18.4 kg/m2, and 44
(37%) patients had cavities on chest radiograph. Seventy-six
(56%) were HIV infected with a median CD4 count of 163
cells/µL. Twenty-five (33%) HIV-infected patients were on
ART at recruitment.
Adherence to medication was good; only 3 (2%) patients
missed ≥3 doses of tuberculosis treatment at any time. Sixty-
four of 76 (85%) HIV-infected patients initiated ART by
study end.
LPA analysis confirmed that all patients with unfavorable
outcomes harbored drug-susceptibleM. tuberculosis at baseline.
Only 2 acquired resistance thereafter; EOT isolates from 1 treat-
ment failure showed rifampicin (rpoB) and isoniazid (katG)
mutations, and posttreatment isolates from 1 relapse showed
an isoniazid (katG) mutation.
Figure 1. Patient screening, recruitment, and follow-up. aFour patients died after sputum smear and conversion to negative. All were human immuno-
deficiency virus (HIV) infected and had no ongoing symptoms of active tuberculosis (TB). As the cause of death was not attributed to TB by the study doctor
or attending physician, these patients were not deemed to have reached a study endpoint and were withdrawn from the analysis; bImmune reconstitution
inflammatory syndrome (IRIS); cOne patient died during the second week of therapy while still sputum smear and culture positive for Mycobacterium tu-
berculosis. The cause of death was attributed as TB; dOne patient redeveloped a productive cough during posttreatment follow-up, and sputum was smear
and culture positive for M. tuberculosis. The cause of death was attributed as TB.
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Table 1 illustrates a trend toward unfavorable outcomes in
HIV-infected individuals. No other clinical factor predicted
outcome.
Evaluation of Bacillary Elimination
SSCC Results
Median baseline bacillary load was 6.19 log10 CFU/mL. Six of
102 (6%) patients remained SSCC culture positive at 8 weeks.
Baseline variability did not influence outcome, but positive 8-
week plates were associated with failure/relapse (OR, 19.33;
95% CI, 3.10–120.63; P = .002; Table 1). Rapid culture conversion
on solid media and losses to contamination meant that only 86
of 133 (64%) patients contributed sufficient data for inclusion in
the SSCC-NLME model. Serial log10 CFU/mL counts for these
patients and individual bacillary elimination profiles from the
bi-exponential model are shown in Supplementary Figures 3A
and 3B. Supplementary Table 1 describes interindividual vari-
ability of the SPER (β); a higher baseline log10 CFU/mL count
was associated with slower SPER. There was a trend toward
slower SPER with advancing age, but no relationship with clin-
ical or radiological factors. Figure 2 shows that a slower SPER
was strongly associated with unfavorable outcome (OR per
0.01 increase in SPER: 0.39; 95% CI, .22–.70; P = .001).
MGIT Results
Median baseline TTP was 4.0 days. Thirty-one of 111 (28%) pa-
tients with 8-week MGIT results remained culture positive. Nei-
ther baseline variability nor 8-week culture positivity was
associated with unfavorable outcomes. Lower contamination
rates, accompanied by greater culture positivity at later time-
points, allowed 124 of 133 (93%) patients to contribute data
to the MGIT–linear mixed effects model. Serial TTP results
and individual bacillary elimination profiles from the model
are shown in Supplementary Figures 4A and 5B. Supplementary
Table 2 describes interindividual MBER (b) variability; longer
baseline TTP was associated with faster MBER, and male sex
Table 1. Characteristics and Clinical Outcomes of Study Patients
Characteristic Total (N = 133)
Unfavorable
Outcome (n = 15)
Stable Cure
(n = 118)
OR for Unfavorable
Outcome (95% CI) P Value
Baseline patient profile
Male sex 89 (67) 10 (67) 79 (67) 0.99 (.32–3.09) .983
Age, median (IQR) 31 (26–37) 30 (27–35) 31 (25–38) 1.02 (.96–1.08) .553
BCG vaccinated 107 (80) 13 (87) 94 (81) 1.51 (.32–7.16) .607
BMI, kg/m2, median (IQR) 18.4 (17.2–20.0) 19.5 (17.8–20.3) 18.3 (17.1–19.9) 1.18 (.96–1.45) .108
HIV infected 76 (56) 12 (80) 64 (54) 3.49 (.94–13.02) .063
CD4 count, cells/µL, median (IQR)a 168 (104–314) 168 (66–349) 164 (104–301) 1.00 (1.00–1.00) 1
% of lung affected on CXR, median (range)b 25 (18–40) 25 (18–38) 25 (18–40) 0.99 (.96–1.03) .605
Presence of cavity ≥4 cm diameterb 44 (37) 4 (31) 41 (38) 0.72 (.21–2.47) .597
Isoniazid-monoresistant M. tuberculosis 2 (2) 0 (0) 2 (2) NA NA
Sputum bacillary load, log10 CFU/mL,
median (IQR)
6.19 (4.94–7.66) 6.56 (5.37–7.59) 6.17 (4.85–7.65) 1.06 (.74–1.52) .748
Sputum MGIT-TTP, d, median (IQR) 4.00 (3.00–7.50) 3.50 (3.50–6.13) 4.50 (3.00–7.50) 0.94 (.80–1.09) .405
%LB+AFB count, % median (IQR)c 28 (13–44) 22 (13–54) 30 (13–43) 1.00 (.97–1.03) .927
Progress during TB therapy
Missed a total of >3 doses of TB therapy 6 (5) 2 (14) 4 (4) 4.75 (.79–28.7) .090
Rise in BMI by 8 wk, kg/m2, median (IQR) 0.72 (0.04–1.34) 0.70 (0.01–1.52) 0.72 (0.11–1.31) 1.03 (.67–1.58) .908
Rise in BMI by end of follow-up, kg/m2,
median (IQR)
1.56 (0.94–2.49) 1.57 (0.19–2.26) 1.54 (0.98–2.48) 0.86 (.56–1.31) .470
Positive sputum smear at 2 mo 22 (18) 1 (8) 21 (19) 0.35 (.04–2.84) .325
SSCC culture positive at 8 wkd 6 (6) 4 (31) 2 (2) 19.33 (3.10–120.63) .002
MGIT culture positive at 8 wkd 31 (28) 6 (46) 25 (26) 2.50 (.77–8.16) .128
Any positive sputum culture at 8 wkd 34 (29) 7 (50) 27 (26) 2.85 (.92–8.88) .071
Data are presented as No. (%) unless otherwise specified.
Abbreviations: BMI, body mass index; CFU, colony-forming units; CI, confidence interval; CXR, chest radiograph; HIV, human immunodeficiency virus; IQR,
interquartile range; %LB+AFB, percentage of lipid body–positive acid-fast bacilli; MGIT, mycobacterial growth indicator tube; NA, not assessed; OR, odds ratio;
SSCC, serial sputum colony counting; TB, tuberculosis; TTP, time to positivity.
a Baseline CD4 counts and antiretroviral therapy for HIV-infected patients only.
b CXRs available for 120 patients.
c Baseline %LB+AFB count available for 69 patients.
d Some 8-week SSCC and MGIT results unavailable due to contamination: n = 102 for SSCC, n = 111 for MGIT, and n = 117 for any culture result.
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was associated with slower MBER. Figure 3 shows a strong as-
sociation between individual MBER estimates and final out-
come (OR of unfavorable outcome per 1-day increase in TTP
per week of therapy: 0.71; 95% CI, .55–.94; P = .015).
Baseline ALTR Microscopy
Baseline sputum samples were assessed for 69 patients. The me-
dian %LB + AFB count was 28%. Two independent observers
analyzed each image, and the interindividual concordance coef-
ficient for %LB + AFB counts (ρc) was 0.84 (95% limits of agree-
ment, −29.45%–21.83%). There were no relationships between
clinical or radiological factors and baseline %LB + AFB counts.
Ten patients with known baseline %LB + AFB counts had
unfavorable outcomes. Fifty-nine had favorable outcomes.
Baseline %LB + AFB count was not associated with clinical
outcome (Table 1), SPER (Supplementary Table 1), or MBER
(Supplementary Table 2).
Serial ALTR Microscopy
A case-control study of 40 patients (10 with unfavorable out-
comes and 30 with favorable outcomes) was undertaken.
Images from 1 patient in each group were discarded due to
poor-quality smears. Data from 38 patients (9 with unfavorable
and 29 with favorable outcomes) were analyzed. Figure 4 illus-
trates that %LB + AFB counts on smears from each group were
similar at baseline and visit 1. By visit 2 there were higher %LB +
AFB counts in the unfavorable outcomes group and by visit 3,
the difference between groups was significant (P = .008). At visit
3, the OR of an unfavorable outcome for each percentage rise in
%LB + AFB count was 1.21 (95% CI, .97–1.50; P = .088).
Figure 2. Pharmacodynamic modeling of bacillary elimination by the se-
rial sputum colony counting (SSCC)–nonlinear mixed effects (NLME) meth-
od. Using best linear unbiased estimates extracted from the SSCC-NLME
model, patients with a higher sterilization phase elimination rate (SPER; β)
were less likely to have unfavorable outcomes (odds ratio per 0.01 log10
colony-forming units [CFU]/mL/day increase in SPER: 0.39, 95% confidence
interval, .22–.70; P = .002).
Figure 3. Pharmacodynamic modeling of bacillary elimination by the my-
cobacterial growth indicator tube linear mixed effects (MGIT-LME) method.
Using best linear unbiased estimates extracted from the MGIT-LME model,
patients with a higher MGIT bacillary elimination rate (MBER, b) were less
likely to have unfavorable outcomes (per day of time to positivity [TTP]/
week increase in MBER: 0.71; 95% confidence interval, .55–.94; P = .015).
Figure 4. Changes in percentage of lipid body–positive acid-fast bacilli
(%LB + AFB) count of serial sputum samples collected from a substudy of
patients during tuberculosis therapy. Results are displayed from serial %
LB + AFB counts in 38 patients (29 with favorable and 9 with unfavorable
outcomes). There were no significant differences in %LB + AFB counts at
baseline or during the first 2 treatment visits between patients with differ-
ent final outcomes. However, the %LB + AFB counts of patients who ulti-
mately had unfavorable outcomes gradually increased during therapy, and
by visit 3 (day 21 or 28) were significantly higher than counts in the favor-
able outcomes groups. Comparisons between groups at visit were made
using a Wilcoxon test.
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DISCUSSION
The failure of clinical trials to shorten tuberculosis treatment
highlights the need for new biomarkers to predict failure/re-
lapse. Our study demonstrates that BER modeling and rising
%LB + AFB counts correlate with clinical endpoints.
When relating biomarkers to long-term outcome, posttreat-
ment relapse should ideally be discriminated from reinfection.
Unfortunately, in this study, detailed sequencing was unavailable
to compare pre- and posttreatment isolates. However, data from
Malawi [36] and South Africa [37] suggest that recurrent tuber-
culosis within 6 months of treatment completion is significantly
more likely to be attributable to relapse, even among HIV-infected
patients, and our unfavorable outcomes all occurred within this
timeframe. LPA analysis indicated that only 2 of 15 patients
with unfavorable outcomes acquired isoniazid or rifampicin
resistance mutations during therapy, supporting the premise
that survival of persister organisms was the main problem.
Sputum culture conversion at 8 weeks is the conventional
phase 2 study endpoint, and an association was observed be-
tween positive 8-week SSCC plates and unfavorable outcomes.
However, 94% of patients (including 73% of failure/relapses)
were not SSCC positive at 8 weeks. As a single 8-week data point
cannot discriminate between individuals with earlier culture
conversion, a large sample would be required to show superior-
ity of any new regimen in a comparative trial [38]. BER models
incorporate information from serial samples to describe varia-
tion in efficacy more precisely.
The SSCC model was consistent with previous studies [12, 16,
39] and compatible with biphasic bacillary clearance [13]. Our
study is the first to describe a relationship between SPERs and
individual patient outcomes. Despite technical challenges (eg,
contamination [18]), these results argue that SPER estimation
is a clinically relevant means of evaluating new tuberculosis
treatments.
Positive 8-week MGIT cultures were not associated with unfav-
orable outcomes, reinforcing observations that phase 2 study results
vary on different media [9–12]. A linear rather than bi-exponential
model described the MGIT-TTP data, reflecting differences in ba-
cillary populations captured by each microbiology technique.
Actively replicating mycobacteria may perish during NaOH
processing and are underrepresented in liquid cultures, whereas
persisters are more extensively revived from broth [12, 40]. Al-
though a linear model is not divisible into early bactericidal and
sterilization phases, the relationship between MBER and outcomes
advocates this as an alternative measure of sterilizing activity.
The %LB + AFB counts were studied to test the premise that
LBs label persister bacteria. These analyses were performed in
patients with high smear-positivity grades because examination
of bacterial subpopulations on scanty slides is difficult. Selec-
tion of cases with high sputum bacillary loads complicates ex-
trapolation of results to patients with paucibacillary or
extrapulmonary disease. However, the observation that higher
%LB + AFB counts after 3–4 weeks of treatment correlates
with failure/relapse is consistent with in vitro data on antibiotic
tolerance [22]. Baseline counts did not affect outcome, suggest-
ing that induction or selection of LB-positive organisms during
therapy is more relevant to treatment response. Despite small
numbers, these pilot data suggest that study of LB-positive
cells may help explain how unfavorable outcomes occur.
There were limitations to this work. It was completed at a sin-
gle site, so geographical variation in bacillary clearance [15, 41]
was not considered. Persister organisms that do not grow on
routine media [42] or are non-acid-fast [21, 22, 43] at microsco-
py may not have been detected. As all patients received the same
drugs, additional studies should evaluate how effectively BER
modeling compares novel regimens.
Overall, the findings that early quantitation of bacillary per-
sistence predicts the risk of unfavorable outcomes and high %
LB + AFB counts during therapy may identify persister bacteria
indicate that these methods should be developed as candidate
surrogate endpoints for phase 2 studies. If reproduced in other
settings, our results could crucially impact the conduct of clin-
ical trials of new tuberculosis regimens.
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